Other approaches involve delivery of compounds such as oridonin (in breast cancer), suppressing NRF2 and increasing apoptosis [45], or modifications of C19-position substituted geldanamycin directed to NRF2 for esophageal squamous cancer [46], or finally, direct inhibition of antioxidant systems or of TRIM24. This evidence concerns the gene NFE2L2 and breast cancer.